Propanc Biopharma, Inc. (Nasdaq: PPCB) issued a scientific comparison of its lead drug candidate PRP against RAS-targeted cancer therapies developed by Revolution Medicines, Inc. (Nasdaq: RVMD) and Erasca, Inc., according to a company press release.

PRP is a fixed-ratio combination of pancreatic proenzymes trypsinogen and chymotrypsinogen, administered once weekly by intravenous injection. The company says the therapy works by inducing differentiation of malignant cells rather than directly killing them or blocking a single signaling pathway. Propanc claims PRP is non-cytotoxic and targets cancer stem cells and epithelial-mesenchymal transition, a process associated with cancer spread and treatment resistance.

In preclinical models of pancreatic ductal adenocarcinoma (PDAC), the company reported greater than 90% mean tumor growth inhibition, a reduction in metastatic burden, and more than a 2.5-fold extension of median overall survival compared to controls. PRP holds FDA Orphan Drug Designation for pancreatic cancer.

Propanc said it plans to file a clinical trial application for a Phase 1b study in advanced cancer patients in the fourth quarter of 2026, enrolling up to 40 to 45 patients. The study will focus on PDAC and other solid tumor indications.

Chief Executive Officer James Nathanielsz said the company expects the Phase 1b study to replicate results from preclinical models and from a prior compassionate use program in which terminal patients were treated at lower doses for up to 18 months.

Revolution Medicines has advanced its RAS(ON) inhibitor daraxonrasib into late-stage trials, with Phase 3 data showing overall survival and progression-free survival benefits in previously treated metastatic PDAC. Erasca's pan-RAS molecular glue ERAS-0015 has shown early clinical signals in RAS-mutant solid tumors. Both companies target RAS signaling pathways present in approximately 90% of PDAC cases.

Propanc's press release positions PRP as a potential complement to RAS-targeted agents, citing preclinical data suggesting it may resensitize chemotherapy-resistant PDAC cells to standard agents such as gemcitabine and nab-paclitaxel.